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Differential aging-related changes of D1, D2, and D3 dopamine receptor expression in 
the striatum 
Mukund M. Patel  
Department of Biology, East Carolina University, Greenville N.C. 27858 
 
ABSTRACT - Aging is associated with a decrease in motor function and a concomitant 
increase in muscle stiffness and tone. The striatum plays a critical role in the control of motor 
function, and it receives strong dopamine (DA) innervation from the substantia nigra. DA 
actions are mediated by both excitatory D1-like (D1 and D5) and inhibitory D2-like (D2, D3, 
and D4) receptors, and D1, D2, and D3 receptor subtypes are thought to be involved in motor 
control, however there is a lack of data on aging-related DA receptor expression levels in the 
striatum. We hypothesize that the observed behavioral aging-related changes in motor control 
might be associated with a change in striatal DA receptor with age, possibly via a shift in 
inhibitory/excitatory DA receptor expression. Three groups of mice (C57BL/6) aged 2 
months (n=4), 1 year (n=4), and 2 years (n=4) were used in this study. Striatal tissue was 
removed from the left hemisphere and Western blots were performed, to detect DA receptors 
D1, D2, and D3 expression levels (Abcam, D1: ab78021; D2: ab21218, D3: ab42114). DA 
receptor expression levels were normalized to ß-actin and the respective DA receptor 
expression in 2-month old animals. We found that with age, D1 receptor expression 
increased continuously and significantly over a ~4 fold increase (383.2 ±62.4 %) in the 1 
year old and reached a ~5 fold increase (474± 49.5 %) in the 2 year old animals (p<0.001). In 
contrast, D2 receptor expression did not change with age (1 year: 110.8 ±2.81 %; 2 year: 
121.0 ± 17.0 %, p = 0.556). Similarly, D3 receptor expression showed no change with age (1 
4 
 
year: 147.1 ± 6.83 %; 2 year: 122.1 ± 11.4 %, p = 0.078). Together these data indicate an 
increase in excitatory striatal DA receptor expression levels with age. Our data suggest that 
this net excitatory increase may play a role in the decline in motor function with age. It is 
tempting to speculate that the increase in D1 receptor expression might be a homeostatic 
compensation for the well-established reduction of DA levels with age. 
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Introduction 
 
Advances in medicine and technology are allowing the population to continue to 
reach a higher age. According to the World Health Organization, the number of people aged 
60 years and older is projected to increase from 605 million to 2 billion, between 2000 and 
2050 (World Health Organization, 2012). In the United States it is projected that by 2050 one 
in five Americans will be part of this elderly population (DHHS-GOV, 2005). For example, 
in the US it is projected that 4.2 million people aged 85 years and older in 2000 will increase 
five-fold by 2040 (DHHS-GOV, 2005).  
 
While the mechanisms for aging are not fully understood, the overall consensus is 
that aging is a complex composite of several different processes that can be distinguished 
from age-related diseases (e.g. Alzheimer’s, Parkinson’s) (Helfand & Inouye, 2002). The 
gradual homeostatic failure at the cellular and the organismic level (Masoro, 1995) involves 
the post-developmental deterioration of physiological, cognitive and emotional 
performances, and is additionally characterized by the declining ability of a system or an 
individual to respond to changes and to stress (Masoro, 1995; Whalley, 2001). This reduction 
of the body’s capabilities to respond to changes leads then to an increasing homeostatic 
imbalance and an increased risk of disease. Moreover, while age-related diseases and, in 
particular, dysfunctions of the nervous system generally occur with an onset only late in life 
(DeKosky & Marek, 2003), aging is a continuous process that starts in humans at a relatively 
early age (between 30 and 40 yrs) and continues until end of life with a nearly constant linear 
decline of physiological functions (Masoro, 1995). 
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One of the most notable dysfunctions developing with normal aging is a gradual 
decline in motor function. This change in motor behavior in the elderly is shown as reduced 
speed and motor activity, slowed reaction time, impaired coordination (Ropper & Samuels, 
2009), slowed initiation of movement (Newman, LeWitt, Jaffe, Clane, & Larsen, 1985; 
Morgan, Phillips, Bradshaw, Iansek, & Bradshaw, 1994), slowed execution of movement 
(Morgan, Phillips, Bradshaw, Iansek, & Bradshaw, 1994), shuffling gait (McGeer, McGeer, 
& Suzuki, 1977; Newman, LeWitt, Jaffe, Clane, & Larsen, 1985), deterioration of gait 
(Ropper & Samuels, 2009), and other motor signs involving a general poverty of movement 
(Mortimer, 1988; Critchley, 1956). In particular, as age increases a decreased stability may 
result in a slower walking pace with shorter steps in order to maintain balance while walking 
(Ropper & Samuels, 2009; Mortimer, 1988). Consequently, a daily task such as walking 
becomes much more difficult and may contribute to the loss of independence by the elderly 
(Mortimer, 1988; Joseph & Roth, 1988). 
 
The striatum, consisting of the caudate nucleus and putamen in the basal ganglia of 
the brain, is a key structure in the central nervous system involved in motor control (Kandel, 
Schwartz, &Jessell, 1995) (Figure 1). The striatum is composed to ~90% of medium spiny 
neurons (MSNs). The striatum is has two types of MSNs. MSN projecting from the striatum 
to the Globus Pallidus (striato-pallidal) MSNs tend to express D2 receptors, while D1 
receptors are highly expressed on striato-nigral MSNs (Surmeier, et al., 2010). The striatum 
is innervated by the substantia nigra (SN), the main dopamine (DA) producing-structure in 
the brain, and these innervations form the nigrostriatal dopaminergic system 
10 
 
The Striatum 
 
 
 
 
 
 
 
 
 
 
Figure 1. Motor function is controlled largely by the brain. Within the brain the striatum, 
shown in blue, is the main relay for motor coordination, and it is composed of the Caudate 
Nucleus and the Putamen. The striatum is heavily innervated by the Substantia nigra (SN), 
shown in orange. Neurons originating from the SN are dopamine producing or dopaminergic 
neurons. These neurons form the nigrostriatal pathway.  
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(Bové, Prou, Perier, &Przedborski, 2005). The basal ganglia and the striatum execute 
intentional motor programs and suppress other unintentional motor programs (Kandel, 
Schwartz, &Jessell, 1995; Darbin, 2012). The basal ganglia are also thought to play a role in 
executing complex motor programs or movements, along with “planning, initiation, and 
control of voluntary movement (Darbin, 2012)” (Joseph & Roth, 1988). 
 
The importance of the striatum in motor function is evident, as pharmacological or 
surgical lesions of the striatal dopaminergic system in animals mimicked Parkinson’s disease 
(PD) (Joseph & Roth, 1988). PD has been characterized as the loss of nigral dopaminergic 
cells in the nigrostriatal pathway, which leads to a depletion of DA (Darbin, 2012; Bové, 
Prou, Perier, & Przedborski, 2005; Duty & Jenner, 2011; Joseph & Roth, 1988; Mortimer, 
1988). The compounds reserpine and alpha-methyl-p-tyrosine are used to mimic the 
neurochemistry of PD by significantly decreasing the DA content of the SN (~85%) and the 
striatum (>95%) (Duty & Jenner, 2011). This decrease in DA content causes changes in 
motor behavior such as akinesia (Duty & Jenner, 2011), compromised postural tone (Joseph 
& Roth, 1988), and hind leg rigidity (Duty & Jenner, 2011). Neurotoxins 6-
hydroxydopamine (6-OHDA) and N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
have been used in animals to induce Parkinsonism. 6-OHDA injected into nigrostriatal fibers 
degenerates dopaminergic neurons, which can cause akinesia, limb dysfunction, rigidity, and 
impaired orientation to sensory stimuli (Joseph & Roth, 1988; Duty & Jenner, 2011). MPTP, 
intravenously injected, also degenerates dopaminergic nigrostriatal neurons, causing tremor, 
rigidity, slowness of movement, postural instability, and freezing (Bové, Prou, Perier, & 
Przedborski, 2005). In addition to the clinical evidence of PD showing that the striatal DA 
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system is involved in changes in motor function with age, studies have shown that normal 
aging leads to neurochemical changes in the striatum. According to a study by McGeer et al. 
(1977), the enzyme tyrosine hydroxylase (TH) shows a significant decrease with age in the 
striatum, in addition to an aging-related loss of nigral dopaminergic cells innervating the 
striatum. TH is an enzyme involved in the synthesis of DA, and can serve as a neurochemical 
biomarker for DA synthesis. They showed that the 400,000 nigral cells at birth decline to less 
than 200,000 by age 75. Other studies have extrapolated that by the age 100 dopaminergic 
nigral cell count would be 140,000, which is comparable to the nigral cell counts of PD 
patients at 60,000-120,000 (Joseph & Roth, 1988). Thus it is evident that the striatal 
dopaminergic system is an important part of motor control and aging. 
 
DA is a catecholaminergic neurotransmitter derived from the amino acid tyrosine 
(Beaulieu &Gainetdinov, 2011). DA and DA producing neurons are mainly located in the 
brain (Missale, Nash, Robinson, Jaber, & Caron, 1998; Beaulieu &Gainetdinov, 2011). 
Within the brain 4 major DA pathways have been identified, the nigrostriatal, mesolimbic, 
mesocortical, and the tuberoinfundibular pathways (Beaulieu &Gainetdinov, 2011). DA is 
involved in a variety of functions within the Central Nervous System (CNS). For example 
DA plays a role in motor function, voluntary movement, cognition, emotion, positive 
reinforcement, food intake, and endocrine regulation (Beaulieu &Gainetdinov, 2011).  
 
DA actions are mediated by five G protein-coupled DA receptors, D1 through D5 
(Beaulieu &Gainetdinov, 2011). This family of DA receptors is divided into two classes, the 
D1-like and D2-like receptors (Figure 2 A). The D1-like receptors consist of DA receptors 
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D1 and D5. The D2-like receptors consist of DA receptors D2, D3, and D4. The D1-like and 
D2-like division has somewhat disparate molecular structures. The D1-like receptors D1 and 
D5 are 80% homologous in receptor structure, while the D2-like receptors D3 and D4 are 
75% and 53% homologous to the D2 receptor, respectively (Beaulieu &Gainetdinov, 2011) 
There is strong evidence for both receptor families in the striatum (for example: (Beckstead, 
1988 ; Broaddus & Bennett Jr., 1990; Gerfen, et al., 1990; Levey, et al., 1993; Aizman, et al., 
2000; Chu, Wilczynski, & Wilcox, 2001; Bertran-Gonzalez, et al., 2008)). Functionally DA 
receptors differentially regulate second messenger pathways by either increasing (D1-like: 
through the coupled Gs/olf G protein) or decreasing (D2-like: through the coupled Gi/o G 
protein) the activity of adenylate cyclase (AC) (Beaulieu &Gainetdinov, 2011). Additionally, 
the affinity of the different receptor subtypes towards DA is D3>D4>D2~D5>>D1 (data 
compiled from http://pdsp.med.unc.edu/). Thus based on the DA receptor subtypes affinity 
for DA, at low levels of DA release, inhibitory actions promoted by D2-like receptors are 
likely to dominate overall DA effects while excitatory effects mediated by D1-like receptors 
are likely to occur only at higher DA doses (Barrière, Mellen, &Cazalets, 2004; Han& 
Whelan, 2009) (Figure 2 B and C). A recent study demonstrated such dose-dependent effects 
of the different DA receptor subtypes on the motor systems when tested in the isolated spinal 
cord (Clemens, Belin-Rauscent, Simmers, & Combes, 2012).  
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Dopamine Receptor Affinities 
 
 
 
 
 
 
 
 
 
Figure 2. (A) Dopamine is a neurotransmitter and its actions are mediated by DA receptors 
D1 through D5. This family of DA receptors is divided into two classes the D1-like (blue) 
and D2-like receptors (red). D1-like receptors consist of D1 and D5 receptors and they tend 
to mediate excitatory actions. While D2-like receptors consist of D2, D3, and D4 receptors 
and they tend to mediate inhibitory actions. Based on previous studies it has been shown that 
D2-like receptors have a higher affinity for DA when compared to D1-like receptors. (B) 
Therefore at low concentrations of D2-like receptors mediate inhibitory actions. (C) In 
contrast, at higher concentrations of DA, D1-like receptors are additionally activated and 
their excitatory actions can overcome the inhibitory effects mediated by the D2-like 
receptors.  
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With age, there is a decline in expression of the striatal DA system that is independent 
of diseases such as PD (Reeves, Bench, & Howard, 2002; Collier, et al., 2007; Ishida, 
Okawa, Ito, Shirokawa, & Isobe, 2007; Jucaite, Forssberg, Karlsson, Halldin, &Farde, 2010), 
but there are no data available that address if these changes in the DA system are also 
mirrored at the receptor level in the striatum. As D1-like and D2-like receptors mediate 
opposite effects, and as striatal D1, D2, and D3 receptors are the primary receptors involved 
in motor function (Beaulieu & Gainetdinov, 2011; Missale, Nash, Robinson, Jaber, & Caron, 
1998), we hypothesized that aging-related alterations in the balance of expression levels for 
D1-like and D2-like receptors might be associated with some of behavioral changes observed 
in the elderly. 
 
Therefore, in order to test this hypothesis we determined here the protein receptor 
expression levels of select DA (D1, D2, and D3) receptors in the striatum of differently aged 
mice.  
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Materials &Methods 
 
Animals 
All experimental procedures were approved by the East Carolina University Institutional 
Animal Care and Use Committee (IACUC, AUP Q273a). Male C57BL/6 mice aged at 2 
months (n=4), 1 year (n=4) and 2 years (n=4) were used. Animals were deeply anesthetized 
and decapitated, and the brains were removed from the skull and stored in a tube containing 
RNAlater (Ambion AM7021). The samples were then stored in a -20° C freezer.  
 
Striatal Dissection 
Striatal tissue was dissected out according to the Richfield1 protocol (The Jackson 
Laboratory, 2003). In this study only the left hemisphere was used to harvest the striatal 
tissue, the other hemisphere was stored for additional later analyses in RNAlater at -20° C. 
Briefly, the brain was oriented in a dorso-ventral orientation and the cerebellum was 
dissected off. Then, the midline of the brain was cut to separate the brain into right and left 
hemispheres. The cortex was then carefully peeled off, followed by removing the 
hippocampus. Finally, the striatal tissue obtained was stored in Eppendorf tubes containing 
RNAlater at -20° C for later analysis. 
 
Protein Preparation 
After obtaining the striatal tissue, the protein concentrations were determined for each 
sample. First, the cell lysis solution was prepared with RIPA buffer, protease inhibitor, and 
phosphatase inhibitor. Then, the striatal samples were placed in test tubes, on ice, containing 
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the cell lysis solution. Next, the samples were sonicated and centrifuged for 20 minutes at 
>16,000 x g. The supernatant containing the protein was transferred to new Eppendorf tubes 
and stored at -80° C. Striatal protein concentrations were determined using the EZQ Protein 
Quantification Kit for gel electrophoresis (Molecular Probes, Life Technologies, Grand 
Island, NY). 
 
Gel Electrophoresis 
After determining striatal protein concentrations we performed western blotting of the 
samples. These experiments were done in replicates with different sample layouts and order 
of antibody exposure per gel, to ensure reproducibility and verify consistencies. First, a 
master mix of Laemmli Sample Buffer (Bio-Rad, Hercules, CA) was made, by adding β-
mercaptoethanol to Laemmli Sample Buffer at a 1:20 dilution. Next, each sample was 
prepared with 30 μg of protein, 20 μl of the sample buffer, and RIPA buffer to bring up the 
volume to 40 μl. Then, the samples were boiled for 10 minutes at 95-100° C and loaded into 
an 18-well Criterion TGX Any kD precast gel (Bio-Rad, Hercules, CA). After the gels were 
loaded and the running buffer (25 mM Tris, 192 mM glycine and 0.1% Sodium Dodecyl 
Sulfate) was poured into the gel running apparatus, the protein samples were ran at 100 V 
until the tracking dye reached the bottom of the gel, usually after 2 hours. 
 
Transfer 
Upon completion of the protein samples migrating down the gel, the transfer of protein from 
the gel to an Immobilon-P PVDF transfer membrane (Millipore, Billerica, MA) was 
performed. First, in each transfer, the membranes were activated by a five-minute incubation 
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in methanol. This procedure was followed by preparing the transfer sandwich containing the 
fiber pads, filter paper, gel, and membrane. The sandwich was then placed into the transfer 
apparatus containing chilled transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol). 
Finally, the electrophoretic transfer ran for one hour at 100 V. 
 
Antibody Probing 
After the transfer, the membranes were probed for DA receptors D1, D2, D3, and ß-actin as a 
loading control. First, membranes were placed in a non-fat 5% milk in Tris buffered saline 
plus Tween blocking solution (150 mM NaCl, 50 mM Tris, 0.1% Tween-20, pH 7.4) at 4° C 
overnight. Primary antibody was then prepared in blocking solution and incubated overnight 
at 4° C. The membranes were then washed with Tris buffered saline plus Tween (TBS-T) 
three times before being incubated in secondary antibody. Secondary antibody was also 
prepared in fresh blocking solution. After a one-hour incubation the membranes were washed 
three times again with TBS-T. Then, at room temperature, Amersham ECL Plus Western 
Blotting Detecting Agents (Amersham, GE Healthcare, Pittsburgh, PA) was applied to the 
membrane and incubated in the dark for five minutes, followed by exposing membranes to 
Amersham Hyperfilm Blue (Amersham, GE Healthcare, Pittsburgh, PA). After successfully 
probing for a given protein, the membranes were stripped with stripping buffer containing 60 
mM Tris, 2% Sodium Dodecyl Sulfate, and 0.7% β-mercaptoethanol with a pH 6.7 at 50° C. 
The membranes were then washed in TBS-T five times or until the stripping buffer has been 
completely dissipated. The process was then repeated until all proteins were successfully 
probed. 
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Antibodies & Detection 
For this study, the following primary antibodies to probe for DA receptor expression and ß-
actin were used: 
D1: Dopamine D1 Receptor (ab78021, abcam, Cambridge, MA, used at 1:500) 
D2: Dopamine D2 Receptor (ab21218, abcam, Cambridge, MA, used at 1:800) 
D3: Dopamine D3 Receptor (ab42114, abcam, Cambridge, MA, used at 1:2500) 
ß-actin: ß-actin Loading Control (ab8227, abcam, Cambridge, MA, used at 1:2000) 
 
Secondary HRP-tagged secondary antibodies (goat anti mouse (HAF007)) or goat anti rabbit 
(HAF008, both R&D Systems, Minneapolis, MN) was then used at a dilution of 1:2000 to 
detect the primary antibody binding. 
 
Analysis 
After exposure to the secondary antibody, membranes were photographed and scanned, and 
images were analyzed with a software package Image J (provided by the National Institutes 
of Health), and subsequent statistical analyses were performed with SigmaPlot (version 11). 
Differences between striatal DA receptors D1, D2, and D3 protein expression levels in the 2 
month, 1 year, and 2-year-old animals were determined using one-way ANOVA, followed by 
appropriate post-hoc comparisons.   
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Results 
 
ß-Actin: 
ß-actin, the loading control, allowed us to normalize levels of protein detected by confirming 
that protein loading was the same across the gel. An immunoreactive band at an approximate 
molecular weight of 37 kD was analyzed to yield protein expression levels of ß-actin (Figure 
3 A). Protein expression of ß-Actin expression remained stable and did not significantly 
change with increasing age (Figure 3 B, p = 0.669). 
 
Effects of Aging on Striatal D1 Receptor protein expression levels: 
An immunoreactive band at an approximate molecular weight of 50 kD was analyzed to yield 
protein expression levels of the striatal D1 receptor (Figure 4 A). Striatal D1 receptor protein 
expression levels significantly changed with increasing age. Protein expression levels 
increased significantly by approximately 4-fold from the 2 month old animals (101.0 ± 12.9 
%) to the 1 year old animals (383.2 ±62.4 %), and approximately 5-fold from the 2 month old 
animals to the 2 year old animals (474±49.5 %, p = <0.001). Overall, there was a 
significantly increased expression of the D1 receptor in the striatum with increasing age 
(Figure 4 B).  
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ß-Actin 
Protein Expression Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. (A) Representative x-ray film exposures of 2 month, 1 year, and 2 year old ß-Actin 
protein bands in the mice striatum. (B) Protein expression levels of ß-Actin in the Striatum of 
animals aged at 2 months, 1 year, and 2 years. A one-way ANOVA test was performed to test 
for statistical differences. No significant changes were observed with age (p = 0.669). Values 
are represented as mean value ± SE. 
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Dopamine D1 Receptor 
Protein expression levels 
Normalized to ß-Actin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. (A) Representative x-ray film exposures of 2 month, 1 year, and 2-year-old D1 
receptor protein bands in the mice striatum. (B) Protein expression levels of D1 receptor 
expression of animals aged at 2 months, 1 year, and 2 years, normalized to ß-Actin and the 2 
month-old animals. A one-way ANOVA and Fischer LSD post hoc test was performed to test 
for statistical differences. Statistical significances are shown with lines and (*) from the 2 
month old animals (p = <0.001). Values are represented as mean value ± SE. 
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Effects of Aging on Striatal DA D2 Receptor protein expression levels: 
Next, striatal D2 receptor protein expression levels were obtained from the analysis of an 
immunoreactive band at an approximate molecular weight of 50kD (Figure 5 A). A 
subsequent quantification revealed that, while we observed a slight increase in D2 receptor 
expression with age, this increase was not significant (2 month: 100.0 ± 15.2 %; 1 year: 
110.8 ±2.81 %; 2 year: 121.0 ± 17.0 %, p = 0.556, Figure 5 B).  
 
Effects of Aging on Striatal DA D3 Receptor protein expression levels: 
Finally, striatal D3 receptor protein expression levels were obtained from the analysis of an 
immunoreactive band at an approximate molecular weight of 37kD (Figure 6 A). As for the 
D2 receptor expression, we did not detect any overall significant difference detected with 
increasing age form the 2 month old animals, despite a transient strong increase from 2 
months to 1 year (2 month: 99.6± 17.8 %;1 year: 147.1± 6.83 %; 2 year: 122.1 ± 11.4 %, p = 
0.078, Figure 6 B). 
 
Effects of Aging on Striatal DA Receptor Ratio: 
Based on the expression data reported in Figures 4-6, we next determined the receptor 
expression ratio between D1/D2 and D1/D3. We found that both ratios showed an 
approximate 4-fold increase with increasing age (Figure 7).  
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Dopamine D2 Receptor 
Protein expression levels 
Normalized to ß-Actin 
 
 
 
 
Figure 5. (A) Representative x-ray film exposures of 2 month, 1 year, and 2-year-old Striatal 
D2 receptor protein bands in the mice striatum. (B) Protein expression levels of striatal D2 
receptor expression of animals aged at 2 months, 1 year, and 2 years, normalized to ß-Actin 
and the 2 month-old animals. A one-way ANOVA was performed to test for statistical 
differences. No statistical significance was observed (p = 0.244). Values are represented as 
mean value ± SE. 
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Dopamine D3 Receptor 
Protein expression levels 
Normalized to ß-Actin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. (A) Representative x-ray film exposures of 2 month, 1 year, and 2 year old Striatal 
D3 receptor protein bands in the mice striatum. (B) Protein expression levels of striatal D3 
receptor expression of animals aged at 2 months, 1 year, and 2 years, normalized to ß-Actin 
and the 2 month-old animals. A one-way ANOVA was performed to test for statistical 
differences. No statistical significance was observed (p = 0.078). Values are represented as 
mean value ± SE. 
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Dopamine Receptor Ratio 
 
 
 
 
 
 
 
 
 
 
Figure 7. Ratios of D1/D2 and D1/D3 receptor expression levels of 2 months, 1 year, and 2 
year old mice striatum. BothD1/D2 and D1/D3 ratios showed an approximate 4-fold increase 
from the 2-month-old animals to the 2 year old animals. 
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Discussion 
 
The aim of this study was to examine aging-related changes in protein expression 
levels of striatal D1, D2 and D3 receptors. In this study we used an aging mouse model to 
dissect out striatal tissue from animals aged at 2 month, 1 year, and 2 years and to determine 
through western blotting techniques the corresponding DA receptor expression levels.  
 
The major findings of this study showed a significant increase in striatal D1 receptor 
protein expression levels with age, while we did not observe any significant changes in either 
D2 or D3 receptor protein expression levels with age. Thus these findings show an aging-
related increase in the balance or ratio of protein expression levels for the D1-like and D2-
like receptors in the striatum. As DA-mediated actions via D1 receptors are predominately 
excitatory, while those mediated through D2 and D3 receptors are predominately inhibitory, 
this increase in the ratio of D1-like/D2-like protein receptor expression levels suggests that 
DA-mediated actions in the striatum may undergo a shift towards overall excitation with age 
(Figure 7). This shift at the receptor level may play a role in normal aging-related changes in 
motor-coordination observed in the non-diseased elderly.  
 
Increased striatal D1 receptor expression levels 
The significant increase in DA D1 receptor expression levels with age shown in this 
study adds to various aging-related changes seen in different studies. In a study by Morgan et 
al. (1987) an increased striatal D1 receptor density with age in humans was reported, along 
with an age-related decline in DA levels. In addition, preliminary data from previous 
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experiments done in out lab have also confirmed an age-related increase in spinal cord D1 
receptor protein expression levels. In contrast, studies in humans have reported an age-
dependent decline in striatal D1 receptor (Jucaite, Forssberg, Karlsson, Halldin, & Farde, 
2010; Wang, et al., 1998). In rats a ~30% decline in striatal DA D1 receptor densities has 
been observed with age (Henry, Filburn, Joseph, & Roth, 1986). Henry, Filburn, Joseph, and 
Roth (1986) also examined a small sample of mice which showed no significant age-related 
change in striatal DA D1 receptor. Many others have also reported aging-related declines in 
rat striatal D1 receptor and D1-like receptors binding potentials (Suzuki, Hatano, Sakiyama, 
Kawasumi, Kato, & Ito, 2001) and mRNA (Zhang & Roth, 1997). Araki, Kato, Shuto, 
Fujiwara, and Itoyama (1997) also reported that in rats no significant change was observed in 
binding sites for the striatal D1 receptor with age. It is important to note that the studies 
reporting a decrease in D1 receptor expression based their findings on different experimental 
and functional paradigms, while our study shows that when using Western blot approaches to 
assess striatal D1 receptor protein expression levels, there is a significant age-dependent 
increase. Alternatively, it is also possible that our small sample size of n=4 for each condition 
may have biased our findings. 
 
No significant change in D2 and D3 Receptor expression levels 
In the present study, no significant age-related changes were observed in striatal DA 
D2 and D3 receptors. While examining mRNA levels of rat striatal D2 receptor a study, 
similarly, reported no significant change with age. However, they did report a decreased 
number of binding sites for the D2 receptor with age (Sakata, Farooqui, & Prasad, 1992). 
Another study examining binding sites of rat striatal D2 receptor with age showed no 
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significant change (Araki, Kato, Shuto, Fujiwara, & Itoyama, 1997). In the rat striatum many 
other studies have also shown decreased levels of striatal D2 receptor mRNA (Mesco, 
Carlson, Joseph, & Roth, 1993; Valerio, Belloni, Gorno, Tinti, Memo, & Spano, 1994; 
Mesco, Joseph, Blake, & Roth, 1991; Zhang, Ravipati, Joseph, & Roth, 1995) and binding 
sites (Henry, Filburn, Joseph, & Roth, 1986; Morgan, et al., 1987; Antonini & Leenders, 
1993; Volkow, et al., 1998; Suzuki, Hatano, Sakiyama, Kawasumi, Kato, & Ito, 2001) with 
age. Henry, Filburn, Joseph, and Roth (1986) also examined a small sample of mice, which 
showed a significant decrease in binding sites for the striatal D2 receptor with age. While 
different studies have had varying results, this study is directly examining protein expression 
levels of the striatal D2 receptor using a Western Blotting technique, which showed no 
significant change with age. However, due to our small sample size possible significant 
trends may have not been detected.  
 
Similar to our study, in rats it has also been shown that striatal DA D3 receptor 
mRNA levels does not change with age (Valerio, Belloni, Gorno, Tinti, Memo, & Spano, 
1994).Suzuki, Hatano, Sakiyama, Kawasumi, Kato, and Ito (2001) have also shown that D2-
like receptors binding sites decrease with age in the rat striatum. Overall, similar to the D1 
receptor the striatal DA D2 appears to vary in terms of expression in different experimental 
models and through different techniques. Relatively few stuides have been done on the 
striatal DA D3 receptor protein expression levels with age, so our study provides important 
data with the Western Blotting technique.  
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Theory 
In our hypothesis we think that the changes in protein expression levels of D1, D2, 
and D3 seen in this study may be due to the affinity and changes in DA levels with age. An 
aging-related decline in striatal DA levels has been previously reported in many studies 
(Umegaki, Roth, & Ingram, 2008; Yue, Zeng, Wu, Yi, Zhang, & Chan, 2012; Wang, et al., 
1998; Carlsson & Winblad, 1976; Adolfsson, Gottfires, Roos, & Winblad, 1979; Severson, 
Marcusson, Winblad, & Finch, 1982; Haycock, Becker, Ang, Furukawa, Hornykiewicz, & 
Kish, 2003). From these previous findings and the results of this study, we hypothesize the 
increased striatal DA D1 receptor protein expression might be a response to the decreased 
levels of DA in the striatum with age and the lower affinity for DA when compared to the 
D2-like receptors (Figure 2). In contrast, due to the higher affinity of the D2-like receptors 
(D3 and D2), the decreased DA levels with age might still be sufficient high to activate them. 
Therefore, the changes seen in D1-like and the lack of changes in D2-like receptors may be 
caused by body’s attempt to maintain DA signaling homeostasis with age. 
 
For future studies, a pharmacological approach may be a possible route worth 
exploring. For example, in this study we have reported an aging-related increase in the 
protein expression levels of the striatal DA D1 receptor in mice. With this knowledge the 
question arises if a D1 agonist was administered to the elderly mice, would the result be 
similar in young mice? We hypothesize that the increased expression of the D1 receptor with 
age might lead to a differential treatment effect in young vs. old mice that might be detected 
behaviorally. Thus it may be necessary to adjust the dosages for DA treatment in an age-
appropriated manner. 
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In summary we saw an aging-related increased expression of the D1 receptor leading 
to a possible shift in the balance D1-like/D2-like receptor ratio towards an overall excitation 
in the striatum, which may be associated with changes in motor function observed in the 
elderly. Further research is needed in the aging mouse model to confirm these results and 
elaborate on the mechanism of how this shift in the balance of D1-like/D2-like receptors may 
be associated with the observed changes in motor function. The mechanism behind the 
increase in D1 receptor expression must also be further explored. This research may 
eventually lead to a possible therapy in order to maintain DA receptor levels with age or 
change DA receptor expression in the elderly. 
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